Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysisopen access
- Authors
- Kim, Dam; Cho, Soo-Kyung; Nam, Seoung Wan; Kwon, Hyuk Hee; Jung, Sun-Young; Jeon, Chan Hong; Im, Seul Gi; Kim, Dalho; Jang, Eun Jin; Sung, Yoon-Kyoung
- Issue Date
- 2017
- Publisher
- 대한류마티스학회
- Keywords
- Anti-inflammatory agents; non-steroidal; Etoricoxib; Osteoarthritis; Safety
- Citation
- 대한류마티스학회지, v.24, no.5, pp 293 - 302
- Pages
- 10
- Journal Title
- 대한류마티스학회지
- Volume
- 24
- Number
- 5
- Start Page
- 293
- End Page
- 302
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/5326
- DOI
- 10.4078/jrd.2017.24.5.293
- ISSN
- 2093-940X
2233-4718
- Abstract
- Objective. To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). Methods. A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics. Results. From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration. Conclusion. Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA.
- Files in This Item
-
- Appears in
Collections - College of Pharmacy > School of Pharmacy > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/5326)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.